A Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180 mg Compared to Placebo Added to Background Lipid-Modifying Therapy in Patients With Elevated LDL-C Who Are Statin Intolerant

Trial Profile

A Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180 mg Compared to Placebo Added to Background Lipid-Modifying Therapy in Patients With Elevated LDL-C Who Are Statin Intolerant

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs Bempedoic acid (Primary)
  • Indications Cardiovascular disorders; Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms CLEAR-Serenity; CVOT
  • Sponsors Esperion Therapeutics
  • Most Recent Events

    • 06 Nov 2017 Planned End Date changed from 1 Sep 2018 to 1 Jul 2018.
    • 06 Nov 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Apr 2018.
    • 02 Oct 2017 According to an Esperion Therapeutics media release, top-line results are expected to be announced by the second quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top